Advertisement

Tumor Biology

, Volume 35, Issue 11, pp 10969–10975 | Cite as

Single nucleotide polymorphisms of multidrug resistance gene 1 (MDR1) and risk of chronic myeloid leukemia

  • Kassogue Yaya
  • Dehbi Hind
  • Quachouh Meryem
  • Quessar Asma
  • Benchekroun Said
  • Nadifi Sellama
Research Article

Abstract

Multidrug resistance gene 1 (MDR1) is known for its involvement in the detoxification through the active transport of toxic compounds from diverse origins outside the cells. These compounds could cause injury to cell DNA, which might lead in cancer like chronic myeloid leukemia (CML). Individual inherited genetic differences related to polymorphism in detoxification enzymes could be an important factor not only in carcinogen metabolism but also in susceptibility of cancer. The present study aimed to investigate the association of three single nucleotide polymorphisms (SNPs) of the MDR1 gene in the susceptibility of CML. We successively have determined the genotype profiles of 1236C>T (exon 12); 2677G>T (exon 21), and 3435C>T (exon 26) SNPs by PCR-RFLP in 89 patients and 99 unrelated healthy controls. Logistic regression was used to assess the effect of each SNP on the development of CML. Interestingly, in exon 12, the 1236TT was significantly associated with the susceptibility of CML when compared to the wild type 1236CC (OR 2.7; 95 % CI 1–7.32, p = 0.041). Additionally, the recessive model 1236TT vs. 1236CC/CT showed a risk of 3.3 fold (p = 0.011) with CML. In exon 26, the 3435CT genotype was associated with a reduced risk of CML (OR 0.5; 95 % CI 0.3–1, p = 0.042). In exon 21, the 2677GT genotype seems to have a protective effect (OR 0.6; 95 % CI 0.32–1.1, p = 0.074). Diplolotypes analysis has demonstrated no effect in susceptibility of CML, but 1236CT/3435CC and 1236CC/2677GT were associated with a protective effect. The haplotypes analysis showed no particular trend (global association p = 0.33). Our findings demonstrate that 1236TT in exon 12 might contribute in the susceptibility of CML, while the 3435CT in exon 26 as well as 1236CT/3435CC and 1236CC/2677GT combinations might be protective factors.

Keywords

MDR1 gene Polymorphism CML 

Notes

Acknowledgments

We authors thank the Hassan II Academy of Science and Technology by supporting this study financially.

Conflicts of interest

None

References

  1. 1.
    Geary CG. The story of chronic myeloid leukaemia. Br J Haematol. 2000;110:2–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12623848.PubMedCrossRefGoogle Scholar
  3. 3.
    Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343–56.PubMedGoogle Scholar
  4. 4.
    Deininger MW, O’Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol: Off J Am Soc Clin Oncol. 2003;21:1637–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12668652.CrossRefGoogle Scholar
  5. 5.
    Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15618470.PubMedCrossRefGoogle Scholar
  6. 6.
    Cojbasic I, Macukanovic-Golubovic L. Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Srp Arh Celok Lek. 2010;138:305–8. Available from: http://www.doiserbia.nb.rs/Article.aspx?ID=0370-81791006305C.PubMedCrossRefGoogle Scholar
  7. 7.
    Löffler H, Bergmann J, Hochhaus A, Hehlmann R, Kramer A, and the German CML Study Group. Reduced risk for chronic myelogenous leukemia in individuals with the cytochrome P-450 gene polymorphism CYP1A1*2A. Blood. 2001;98:3874–5. doi: 10.1182/blood.V98.13.3874.
  8. 8.
    Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res. 1994;137:S68–97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8127953.PubMedCrossRefGoogle Scholar
  9. 9.
    Taspinar M, Aydos SE, Comez O, Elhan AH, Karabulut HG, Sunguroglu A. CYP1A1, GST gene polymorphisms and risk of chronic myeloid leukemia. Swiss Med Wkly. 2008;138:12–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18224491.PubMedGoogle Scholar
  10. 10.
    Belitsky GA, Yakubovskaya MG. Genetic polymorphism and variability of chemical carcinogenesis. Biochem Biokhimia. 2008;73:543–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18605979.CrossRefGoogle Scholar
  11. 11.
    Lee JS, Ward WO, Liu J, Ren H, Vallanat B, Delker D, et al. Hepatic xenobiotic metabolizing enzyme and transporter gene expression through the life stages of the mouse. PloS one. 2011;6:e24381. Available fromGoogle Scholar
  12. 12.
    Shimada T. Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet. 2006;21:257–76.PubMedCrossRefGoogle Scholar
  13. 13.
    Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu Rev Physiol. 2003;65:261–311. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12518001.PubMedCrossRefGoogle Scholar
  14. 14.
    Fromm MF. Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology. 2002;181:299–303. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12505329.PubMedCrossRefGoogle Scholar
  15. 15.
    Xu C, Li CY-T, Kong A-NT. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res. 2005;28:249–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15832810.PubMedCrossRefGoogle Scholar
  16. 16.
    Ueda K, Pastan I, Ottesman MM. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem. 1987;262:17432–6.PubMedGoogle Scholar
  17. 17.
    Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA. 1987;84:265–9. Available fromGoogle Scholar
  18. 18.
    Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem. 1989;37:159–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2463300.PubMedCrossRefGoogle Scholar
  19. 19.
    Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S. Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. Drug Metab Pharmacokinet. 2004;19:1–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15499164.PubMedCrossRefGoogle Scholar
  20. 20.
    Andersen V, Ostergaard M, Christensen J, Overvad K, Tjønneland A, Vogel U. Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009;9:407. doi: 10.1186/1471-2407-9-407.
  21. 21.
    Brinar M, Cukovic-Cavka S, Bozina N, Ravic KG, Markos P, Ladic A, et al. MDR1 polymorphisms are associated with inflammatory bowel disease in a cohort of Croatian IBD patients. BMC Gastroenterol. 2013;13:1–7.CrossRefGoogle Scholar
  22. 22.
    Andersen V, Ostergaard M, Christensen J, Overvad K, Tjønneland A, Vogel U. Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009;9:1–11.CrossRefGoogle Scholar
  23. 23.
    Jamroziak K, Młynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol. 2004;72:314–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15059065.PubMedCrossRefGoogle Scholar
  24. 24.
    Elghannam DM, Ibrahim L, Ebrahim MA, Azmy E, Hakem H. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients. Hematol (Amsterdam, Netherlands). 2013;19:123–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23683876.Google Scholar
  25. 25.
    Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Kassogue Y, Dehbi H, Nassereddine S, Quachouh M, Nadifi S. Genotype variability and haplotype frequency of MDR1 (ABCB1) gene polymorphism in Morocco. DNA Cell Biol. 2013;32:582–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23930592.PubMedCrossRefGoogle Scholar
  27. 27.
    Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinforma (Oxford, England). 2006;22:1928–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16720584.CrossRefGoogle Scholar
  28. 28.
    Marzolini C, Paus E, Buclin T, Kim R. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13–33.PubMedCrossRefGoogle Scholar
  29. 29.
    Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood. 1998;91:1749–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9473242.PubMedGoogle Scholar
  30. 30.
    Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science (New York, NY). 2006;314:1930–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17185601.CrossRefGoogle Scholar
  31. 31.
    Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007;67:9609–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17942888.PubMedCrossRefGoogle Scholar
  32. 32.
    Calado RT, Falcão RP, Garcia AB, Gabellini SM, Zago MA, Franco RF. Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells. Haematologica. 2002;87:564–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12031911.PubMedGoogle Scholar
  33. 33.
    Hitzl M, Drescher S, van der Kuip H, Schäffeler E, Fischer J, Schwab M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics. 2001;11:293–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11434506.PubMedCrossRefGoogle Scholar
  34. 34.
    Vivona D, Bueno CT, Lima LT, Hirata RDC, Hirata MH, Luchessi AD, et al. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells Mol Dis. 2012;48:132–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22134106.PubMedCrossRefGoogle Scholar
  35. 35.
    Urayama KY, Wiencke JK, Buffler PA, Chokkalingam AP, Metayer C, Wiemels JL. MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomark Prev. 2007;16:1172–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17548681.CrossRefGoogle Scholar
  36. 36.
    Jamroziak K, Balcerczak E, Calka K, Piaskowski S, Urbanska-Rys H, Salagacka A, et al. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res. 2009;33:332–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18639335.PubMedCrossRefGoogle Scholar
  37. 37.
    Sailaja K, Surekha D, Rao DN, Raghunadharao D. Association of MDR1 gene polymorphism (G2677T) with chronic myeloid leukemia. Biol Med. 2010;2:17–21.Google Scholar
  38. 38.
    Elghannam D, Ibrahim L, Ebrahim M, Azmy E, Hakem H. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients. Hematology. 2014;19:123–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Jamroziak K, Balcerczak E, Smolewski P, Robey RW, Cebula B, Panczyk M, et al. MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol Rep. 2006;58:720–8.PubMedGoogle Scholar
  40. 40.
    Kim R, Leake B, Choo E, Dresser G, Kubba S, Schwarz U, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189–99.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Kassogue Yaya
    • 1
  • Dehbi Hind
    • 1
  • Quachouh Meryem
    • 2
  • Quessar Asma
    • 2
  • Benchekroun Said
    • 2
  • Nadifi Sellama
    • 1
  1. 1.Genetics and Molecular Pathology Laboratory, Medical school of CasablancaUniversity Hassan IICasablancaMorocco
  2. 2.Department of Onco-HematologyIbn Rochd University HospitalCasablancaMorocco

Personalised recommendations